Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study.
Luis Alonso González-NaranjoJaime Alberto Coral-EnríquezMauricio Restrepo-EscobarCarlos Horacio Muñoz-VahosDaniel Jaramillo-ArroyaveAdriana Lucía Vanegas-GarcíaRuth ErasoGloria VásquezFabián JaimesPublished in: Clinical rheumatology (2020)
Among SLE patients, cumulative glucocorticoid dose, lymphopenia, and the use of ≥ 2 immunosuppressants during the last 12 months were associated with active TB infection. Key Points • Among SLE patients, a cumulative dose of glucocorticoids equivalent to 5 mg/day of prednisone during the last 12 months is independently associated with the development of TB. • The use of two or more immunosuppressants during the last 12 months is also a risk factor for TB infection development is SLE patients. • Lymphopenia is predominant in SLE patients with TB, being especially profound in those with disseminated TB. • Renal transplant recipients with SLE also have an elevated risk of TB.
Keyphrases
- systemic lupus erythematosus
- mycobacterium tuberculosis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- disease activity
- patient reported outcomes
- emergency department
- hepatitis c virus
- intellectual disability
- patient reported
- antiretroviral therapy
- electronic health record